Search

Purpose: To investigate the clinical efficacy of avatrombopag, an oral thrombopoietin receptor agonist, versus subcutaneous recombinant human thrombopoietin (rh-TPO) in the treatment of severe thrombocytopenia (TCP) associated with chronic liver disease (CLD). Methods: Clinical data of 250 patients with severe TCP associated with CLD were collected in a single hospital from January 2019 to January 2022. The main parameters measured were the therapeutic response rate, changes in platelets (PLTs), and adverse events. Propensity score matching (PSM) was used to avoid possible selection bias. Results: After PSM, a total of 154 patients were enrolled in the study: 77 in the avatrombopag group and 77 in the rh-TPO group. There was no statistically significant difference between the two groups in the effect of increasing the PLT count (Waldχ² = 1.659, p = 0.198; Waldχ² = 0.220, p = 0.639). In addition, no interaction between time and different medications was found (Waldχ² = 0.540, p = 0.910; Waldχ² = 1273, p = 0.736). Interestingly, in the subgroup analysis, both before and after PSM, avatrombopag showed better clinical efficacy than rh-TPO in the treatment of TCP associated with CLD in Child-Pugh Class A (88.89% vs. 63.41%, p =0.003; 81.33% vs. 61.76%, p = 0.043). Fewer patients reported dizziness in the avatrombopag group than in the rh-TPO group both before and after PSM (7.8% vs. 25.0%; 7.8% vs. 24.7%, p < 0.05). Conclusion: Both before and after PSM, avatrombopag showed better clinical efficacy than rh-TPO in the treatment of TCP associated with CLD in Child-Pugh Class A and showed a lower incidence of dizziness in all patients. [ABSTRACT FROM AUTHOR]

The single-phase voltage loss is a common fault. Once the voltage-loss failure occurs, the amount of electrical energy will not be measured, but it is to be calculated so as to protect the interest of the power supplier. Two automatic calculation methods, the power substitution and the voltage substitution, are introduced in this paper. Considering the lack of quantitative analysis of the calculation error of the voltage substitution method, the grid traversal method and MATLAB tool are applied to solve the problem. The theoretical analysis indicates that the calculation error is closely related to the voltage unbalance factor and the power factor, and the maximum calculation error is about 6% when the power system operates normally. To verify the theoretical analysis, two three-phase electrical energy metering devices have been developed, and verification tests have been carried out in both the lab and field conditions. The lab testing results are consistent with the theoretical ones, and the field testing results show that the calculation errors are generally below 0.2%, that is correct in most cases. [ABSTRACT FROM AUTHOR]